Trials / Completed
CompletedNCT03470545
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- MyoKardia, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mavacamten | mavacamten capsules |
| DRUG | Placebo | placebo oral capsule |
Timeline
- Start date
- 2018-05-29
- Primary completion
- 2020-03-14
- Completion
- 2020-05-06
- First posted
- 2018-03-20
- Last updated
- 2021-10-04
- Results posted
- 2021-10-04
Locations
71 sites across 13 countries: United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03470545. Inclusion in this directory is not an endorsement.